We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.43 | 0.33% | 131.15 | 131.91 | 130.13 | 130.13 | 7,757,432 | 01:00:00 |
From Apr 2021 to Apr 2024
By Stephen Nakrosis
Sellas Life Sciences Group Inc. shares rose premarket Wednesday, after the company said it saw promising updated clinical data and initial immunobiological data from an ovarian cancer treatment.
The biopharmaceutical company said updated data from its ongoing Phase 1/2 study of Galinpepimut-S combined with Keytruda to treat WT1+ advanced ovarian cancer showed all patients alive and 45.5% continuing investigational therapy as of the latest follow-up.
At 9:14 a.m. ET, Sellas shares were trading 14.8% higher at $15.01. Volume at the time topped 443,000 shares.
The stock closed Tuesday down 4.8% at $13.07 a share.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
June 30, 2021 09:37 ET (13:37 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
